Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EJS ACT-PD: Platform Trial for Parkinson's
NCT07207057Phase 3Recruiting
- Sponsor
- University College London
- Start
- Sep 2025
- Primary completion
- May 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, terazosin in Parkinson's disease (PD), sponsored by University College London. Started Sep 2025; status: recruiting.
02
Drugs
telmisartanterazosin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07207057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207057.